A. Goy Et Al. , "Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib," 55th Annual Meeting of the American-Society-of-Hematology , vol.122, Louisiana, United States Of America, 2013
Goy, A. Et Al. 2013. Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. 55th Annual Meeting of the American-Society-of-Hematology , (Louisiana, United States Of America).
Goy, A., Williams, M. E., Besisik, S., Drach, J., Ramchandren, R., Robertson, M. J., ... Avivi, I.(2013). Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib . 55th Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America
Goy, Andre Et Al. "Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib," 55th Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America, 2013
Goy, Andre Et Al. "Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib." 55th Annual Meeting of the American-Society-of-Hematology , Louisiana, United States Of America, 2013
Goy, A. Et Al. (2013) . "Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib." 55th Annual Meeting of the American-Society-of-Hematology , Louisiana, United States Of America.
@conferencepaper{conferencepaper, author={Andre Goy Et Al. }, title={Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib}, congress name={55th Annual Meeting of the American-Society-of-Hematology}, city={Louisiana}, country={United States Of America}, year={2013}}